Reviewer’s report

Title: Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer

Version: 1 Date: 16 October 2012

Reviewer: Oliver Renner

Reviewer’s report:

Report of Oliver Renner

In the manuscript “Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer”, Yip-Schneider and colleagues describe the effects of this combination treatment on the development of pancreatic cancer. Using a genetically engineered mouse model, they investigate the combination of the standard-of-care agent gemcitabine, which is known to activate the NFkB signaling pathway, with the NFkB-inhibiting compound Dimethylaminoparthenolide (DMAPT).

The manuscript is well structured and the underlying questions, which are based on an earlier study, are clearly stated. The experimental procedures and the results are sound and very well described and presented. It was a pleasure for me to read this manuscript.

I recommend publishing the presented manuscript without further changes.

Best regards,
Oliver Renner

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests.